Proliferation and survival of mammary carcinoma cells are influenced by culture conditions used for ex vivo expansion of CD34+ blood progenitor cells

Blood

Volumn 93, Issue 2, 1999, Pages 746-755

  Spyridonidis, A ^b   Bernhardt, W ^b   Eehringer, D ^b   Kohler G ^b   Azemar, M ^b   Pflug, A ^b   Henschler, R ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CD34 ANTIGEN; ERYTHROPOIETIN; INTERLEUKIN 1BETA; INTERLEUKIN 3; INTERLEUKIN 6; STEM CELL FACTOR; TRANSFORMING GROWTH FACTOR BETA1;

ADULT; AGED; ARTICLE; ASCITES; BONE MARROW PURGING; BREAST CARCINOMA; CELL PROLIFERATION; CELL SURVIVAL; CLONOGENESIS; CONTROLLED STUDY; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; PLEURA EFFUSION; PRIORITY JOURNAL;

EID: 0033555977     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v93.2.746     Document Type: Article

References (59)

1. Antman KH, Rowlings PA, Vaughan WP, Pelz CJ, Fay JW, Fields KF, Freytes CO, Gale RP, Hillner BE, Holland HK, Kennedy MJ, Klein JP, Lazarus HM, McCarthy PL, Saez R, Spitzer G, Stadtmauer EA, Williams SF, Wolff S, Sobocinski KA, Armitage DO, Horowitz MM: High-dose chemotherapy with autologous hematopoietic stem-cell support for breast cancer in North America. J Clin Oncol 15:1870, 1997
2. Bezwoda WR, Seymour I, Dansey RD: High dose chemotherapy with hematopoietic rescue as primary treatment for metastatic breast cancer: A randomized trial. J Clin Oncol 13:2483, 1995
3. Peters WP: High dose chemotherapy with autologous bone marrow transplantation for the treatment of breast cancer, in DeVita VTHS, Rosenberg SA (eds): Important Advances in Oncology. Philadelphia, PA, Lippincott, 1995, p 215
4. Ross AA, Cooper BW, Lazarus HM, Mackay W, Moss TJ, Ciobanu N, Tallman MS, Kennedy MJ, Davidson NE, Sweet D, Winter C, Akard L, Jansen J, Copelan E, Meagher RC, Herzig RH, Klumpp RT, Kahn DG, Warner NE: Detection and viability of tumor cells in peripheral blood stem cell collections from breast cancer patients using immunocytochemical and clonogenic assay techniques. Blood 82:2605, 1993
5. Brugger W, Bross KJ, Glatt M, Weber F, Mertelsmann R, Kanz L: Mobilization of tumor cells and hematopoietic progenitor cells into peripheral blood of patients with solid tumors. Blood 83:636, 1994
6. Rill DR, Santana VM, Roberts WM, Nilson T, Bowman LC, Krance RA, Heslop HE, Moen RC, Ihle JN, Brenner MK: Direct demonstration that autologous bone marrow transplantation for solid tumors can return a multiplicity of tumorigenic cells. Blood 84:380, 1994
7. Deisseroth AB, Zu Z, Claxton D, Hanania EG, Fu S, Ellerson D, Goldberg L, Thomas M, Janicek K, Anderson WF, Hester J, Korbling M, Durett A, Moen R, Berenson R, Heimfeld S, Hamer J, Calvert L, Tibbits P, Talpaz M, Kantarjian H: Genetic marking shows that Ph+ cells present in autologous transplants of chronic myelogenous leukemia (CML) contribute to relapse after autologous bone marrow transplantation for CML. Blood 83:3068, 1994
8. Brenner MK, Rill DR, Moen RC, Krance RA, Mirro JJR, Anderson WF, Ihle JN: Gene marking to trace origin of relapse after autologous bone marrow transplantation. Lancet 341:85, 1993
9. Kessinger A, Reed E, Vaughan W, Sharp J: Clinical outcome of patients with breast cancer and gynecological epithelial tumors undergoing high dose therapy and peripheral blood stem cell transplantation with or without minimally contaminated apheresis harvests. Proc Am Soc Clin Oncol 12:74, 1993 (abstr)
10. Glück S, Ross AA, Goldstein L, Layton T, Ostrander A, Porter K, Ho AD: Detection of breast cancer cells in the apheresis product and their potential clinical significance. Blood 88:605a, 1996 (abstr, suppl 1)
11. Brockstein BE, Ross AA, Moss TJ, Kahn DG, Hollingsworth K, Williams SF: Tumor cell contamination of bone marrow harvest products: Clinical consequences in a cohort of advanced-staged breast cancer patients undergoing high-dose chemotherapy (HDC). J Hematother 5:617, 1996
12. Shpall EJ, Jones RB, Bearman SI, Franklin WA, Archer PG, Bitter M, Claman HN, Stemmer SM, Purdy M, Myers SM, Hami L, Taffs S, Heimfeld S, Hallagan J, Berenson RJ: Transplantation of enriched CD34-positive autologous marrow into breast cancer patients following high-dose chemotherapy: Influence of CD34-positive peripheral-blood progenitors and growth factors on engraftment. J Clin Oncol 12:28, 1994
13. Mapara MY, Körner IJ, Hildebrandt M, Bargou R, Krahl D, Reichardt P, Dörken B: Monitoring of tumor cell purging after highly efficient immunomagnetic selection of CD34 cells from leukapheresis products in breast cancer patients: Comparison of immunocytochemical tumor cell staining and reverse transcriptase-polymerase chain reaction. Blood 89:337, 1997
14. + cells and unseparated peripheral blood progenitor cells. Blood 80:1405, 1992
15. Petzer AL, Hogge DE, Lansorp PM, Reid DS, Eaves CJ: Self-renewal of primitive human hematopoietic cells (long-term-culture-initiating cells) in vitro and their expansion in defined medium. Proc Natl Acad Sci USA 93:1470, 1996
16. + peripheral blood progenitor cells. Blood 84:2898, 1994
17. Muench MO, Firpo MT, Moore MAS: Bone marrow transplantation with interleukin-1 plus kit-ligand ex vivo expanded bone marrow accelerates hematopoietic reconstitution in mice without loss of stem cell lineage and proliferative potential. Blood 81:3463, 1993
18. Brugger W, Heimfeld S, Berenson R, Mertelsmann R, Kanz L: Ex vivo expanded peripheral blood CD34+ cells mediate hematopoietic recovery after high dose chemotherapy. N Engl J Med 333:283, 1995
19. Ross AA, Loudovaris M, Hazelton B, Weaver CH, Schwartzberg L, Bender JG: Immunocytochemical analysis of tumor cells in pre-and post-culture peripheral blood progenitor cell collections from breast cancer patients. Exp Hematol 23:1478, 1995
20. + peripheral blood progenitor cells. Implications for the expansion of contaminating epithelial tumor cells. Blood 88:2707, 1996
21. Purdy MH, Hogan CJ, Hami L, McNiece I, Franklin W, Jones RB, Bearman SI, Berenson RJ, Cagnoni PJ, Heimfeld S: Large volume ex vivo expansion of CD34-positive hematopoietic progenitor cells for transplantation. J Hematother 4:515, 1995
22. Pantel K, Dickmans A, Zippelius A, Klein C, Shi J, Hoechtlen-Vollmar W, Schlimok G, Weckermann D, Oberneder R, Fanning E, Riethmüller G: Establishment of micrometastatic carcinoma cell lines: A novel source of tumor cell vaccines. J Natl Cancer Inst 87:1162, 1995
23. Sharp JG, Bishop M, Chan WC, Greiner T, Joshi SS, Kessinger A, Reed E, Sanger W, Tarantolo S, Traystman M: Detection of minimal residual disease in hematopoietic tissues. NY Acad Med 770:242, 1995
24. Garbe A, Spyridonidis A, Möbest D, Mertelsmann R, Henschler R: Transforming growth factor-beta 1 delays formation of clonogenic cells from CD34+ cells and protects primitive progenitors (LTCIC) in liquid culture in the presence of positive hematopoietic regulators. Ann Hematol 73:354, 1996 (suppl II)
25. Möbest D, Mertelsmann R, Henschler R: Serum-free ex vivo expansion of CD34+ hematopoietic progenitor cells. Biotechnol Bioeng 60:341, 1998
26. Latza U, Niedobitek G, Schwarting R, Nekarda H, Stein H: Ber-Ep4: New monoclonal antibody which distinguishes epithelia from mesothelial. J Clin Pathol 43:213, 1990
27. + hematopoietic progenitor cells with recombinant immunotoxins. Blood 91:1820, 1998
28. Diaz-Arias AA, Loy TS, Bickel JT, Chapman RK: Utility of Ber-Ep4 in the diagnosis of adenocarcinoma in effusions: An immunocytochemical study of 232 cases. Diag Cytopathol 9:516, 1993
29. Sheibany K, Shin SS, Kezirian J, Weiss LM: Ber-Ep4 antibody as a discriminant in the differential diagnosis of malignant mesothelioma versus adenocarcinoma. Am J Surg Pathol 15:779, 1991
30. Barberis MC, Faleri M, Veronese S, Casadio C, Viale G: Calretinin. A selective marker of normal and neoplastic mesothelial cells in serous effusions. Acta Cytol 41:1757, 1997
31. Robertson KW, Reeves JR, Smith G, Keith WN, Ozanne BW, Cooke TG, Stanton PD: Quantitative estimation of epidermal growth factor receptor and c-erbB2 in human breast cancer. Cancer Res 56:3823, 1996
32. Jeschke M, Wels W, Dengler W, Imber R, Stöcklin E, Groner B: Targeted inhibition of tumor cell growth by recombinant heregulin-toxin fusion proteins. Int J Cancer 60:730, 1995
33. Szöllösi J, Balazs M, Feuerstein BG, Benz CC, Waldman FM: ERBB-2 (HER2/neu) gene copy number, p185HER-2 overexpression, and intratumor heterogeneity in human breast cancer. Cancer Res 55:5400, 1995
34. + progenitor cells by stem cell factor, interleukin-(IL)-1 beta, IL-6, IL-3, interferon-gamma, and erythropoietin. Blood 81:2579, 1993
35. Mazars P, Barboule N, Baldin V, Vidal S, Ducommun B, Valette A: Effects of TGF-betal on the cell cycle regulation of human breast adenocarcinoma (MCF-7) cells. FEBS Lett 362:295, 1995
36. Garbe A, Spyridonidis A, Möbest D, Schmoor C, Mertelsmann R, Henschler R: Transforming growth factor-beta 1 delays formation of granulocyte-macrophage colony-forming cells, but spares more primitive progenitors during ex vivo expansion of CD34+ haematopoietic progenitor cells. Br J Haematol 99:951, 1997
37. Berdel W, Danhauser-Riedl S, Steinhauser G, Winton E: Various human hematopoietic growth factors (IL-3, GM-CSF, G-CSF) stimulate clonal growth of nonhematopoietic tumor cells. Blood 73:80, 1989
38. Sandsrrom CE, Miller WM, Papoutsakis ET: Serum-free media for cultures of primitive and mature hematopoietic cells. Biotechnol Bioeng 43:706, 1994
39. Srour EF, Brandt JE, Bridell RA, Gringsby S, Leemhuis T, Hoffman R: Long term generation and expansion of human primitive hematopoietic progenitor cells in vitro. Blood 81:661, 1993
40. Band V, Zajchowski D, Swisshelm K, Trask D, Kules V, Cohen C, Connolly J, Sager R: Tumor progression in four mammary epithelial cell lines derived from the same patient. Cancer Res 50:7351, 1990
41. Cailleau R, Mackay B, Young RK, Reeves WJ: Tissue culture studies on pleural effusions from breast carcinoma patients. Cancer Res 34:801, 1974
42. Sharp JG, Mann SL, Kessinger A, Joshi SS, Crouse DA, Weisenburger DD: Detection of occult breast cancer cells in cultured pretransplantation bone marrow, in Dicke KA, Spitzer G, Jagannath S (eds): Autologous Bone Marrow Transplantation, vol III. Houston, TX, The University of Texas, MD Anderson Cancer Center, 1987, p 497
43. Emerman JT, Stingl J, Petersen A, Shpall EJ, Eaves CJ: Selective growth of freshly isolated human breast epithelial cells cultured at low concentrations in the presence or absence of bone marrow cells. Breast Cancer Res Treat 41:147, 1996
44. Ethier SP, Mahacek ML, Gullick WJ, Frank TS, Weber BL: Differential isolation of normal luminal mammary epithelial cells and breast cancer cells from primary and metastatic sites using selective media. Cancer Res 53:627, 1993
45. Dairkee SH, Paulo EC, Traquina P, Moore DH, Ljung B, Smith HS: Partial enzymatic degradation of stroma allows enrichment and expansion of primary breast tumor cells. Cancer Res 57:1590, 1997
46. Sharp IG, Mann SL, Murphy B, Weekes C: Culture methods for the detection of minimal tumor contamination of hematopoietic harvests: A review. J Hematother 4:141, 1995
47. Aapro MS, Eliason JF, Krauer F, Alberto P: Colony formation in vitro as a prognostic indicator for primary breast cancer. J Clin Oncol 5:890, 1987
48. Danforth DN, Sgagias MK: Interleukin-1α and Interleukin-6 act additively to inhibit growth of MCF-7 cancer cells in vitro. Cancer Res 53:1538, 1993
49. Gaffney EV, Koch G, Tsai SC, Loucks T, Lingenfelter SE: Correlation between human cell growth response to interleukin 1 and receptor binding. Cancer Res 48:5455, 1988
50. Aakvaag A, Utaaker E, Thorsen T, Lea O, Lahooti H: Growth control of human mammary cancer cells (MCF-7 cells) in culture: Effect of estradiol and growth factors in serum-containing medium. Cancer Res 50:7806, 1990
51. Nachbaur D, Denz H, Zwierzina H, Schmalze F, Huber H: Stimulation of colony formation of various human carcinoma cell lines by rhGM-CSF and rhIL-3. Cancer Lett 50:197, 1990
52. Dedhar S, Gaboury L, Galloway P, Eaves C: Human granulocyte-macrophage colony-stimulating factor is a growth factor acting on a variety of cell types of nonhemopoietic origin. Proc Natl Acad Sci USA 85:9253, 1988
53. Jorasckewitz M, Trijssenaar J, Krumwieh D, Neukam D, Meyer DJ, Freund M, Poliwoda H, Hanauske A: Recombinant cytokines stimulate in vitro colony formation of human tumors. Proc Am Assoc Cancer Res 30:1299, 1989 (abstr)
54. Freiss G, Prebois C, Vignon F: Control of breast cancer cell growth by steroid and growth factors: Interactions and mechanisms. Breast Cancer Res Treat 27:57, 1993
55. Emerman JT, Eaves CJ: Lack of effect of hematopoietic growth factors on human breast epithelial cell growth in serum-free primary culture. Bone Marrow Transplant 13:285, 1994
56. Eaves CJ, Cashman JD, Kay RJ, Dougherty GJ, Otsuka T, Gaboury LA, Hogge DE, Lansdorp PM, Humphries RK: Mechanisms that regulate the cell cycle status of very primitive hematopoietic cells in long-term bone marrow cultures. II. Analysis of positive and negative regulators produced by stromal cells within the adherent layer. Blood 78:110, 1991
57. Massagué J, Polyak K: Mammalian antiproliferative signals and their targets. Curr Opin Genet Dev 5:91, 1995
58. Knabbe C, Lippman ME, Wakefield LM, Flanders KC, Kasid A, Derynck R, Dickson RB: Evidence that transforming growth factor-beta is a hormonally regulated negative growth factor in human breast cancer cells. Cell 48:417, 1987
59. Zugmaier G, Lippman ME: Effects of TGF-beta on normal and malignant mammary epithelium. Ann NY Acad Sci 593:272, 1990